![ORIC Pharmaceuticals, Inc. logo](/logos/ORIC.webp)
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Overview | Financials
Company Name | ORIC Pharmaceuticals, Inc. |
Symbol | ORIC |
Currency | USD |
Price | 9.65 |
Market Cap | 680,735,125 |
Dividend Yield | 0% |
52-week-range | 5.27 - 16.65 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jacob M. Chacko M.B.A., M.D. |
Website | https://www.oricpharma.com |
An error occurred while fetching data.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD